5th Joint triennial congress of the European and Americas Committees
for Treatment and Research in Multiple Sclerosis
Amsterdam, The Netherlands
19.10.2011 - 22.10.2011
Please select a day:
19.10.2011
20.10.2011
21.10.2011
22.10.2011
Search

Personal programme
Please enter your email address here in order to bring up your personal programme




Home


Friday, October 21, 2011

- Click on a checkbox to select a whole session.
- Session titles which are underlined can be clicked upon to show further details.
- Individual programme items can also be selected.
- Go to another day to select further points or click on display to show your saved personal programme.
08:00 Allergan
Multimodal management in MS - improving quality of life (Satellite Symposium)
09:15 Platform presentation of selected abstracts on immunology (Free Communications I)
09:15 Platform presentation of selected abstracts on imaging (Free Communications II)
09:15 Platform presentation of selected abstracts on therapeutics (Free Communications III)
10:45 Grey matter damage in MS (Parallel Session 7)
10:45 The importance of B-cells in MS (Parallel Session 8)
10:45 How to measure clinical progression (Parallel Session 9)
12:45 Novartis Pharma AG
Fingolimod: pioneering innovation in MS treatment (Satellite Symposium)
14:00 Cognitive decline in MS (Parallel Session 10)
14:00 Cell based therapy in MS (Parallel Session 11)
14:00 New developments in the epidemiology of MS (Parallel Session 12)
15:30 Poster Viewing Session II:
15:30 Diagnosis & differential diagnosis 2 (Poster topic 34)
15:30 MS variants 2 (Poster topic 35)
15:30 Paediatric MS 2 (Poster topic 36)
15:30 Natural course 2 (Poster topic 37)
15:30 Epidemiology 2 (Poster topic 38)
15:30 MS symptoms 2 (Poster topic 39)
15:30 Clinical assessment tools 2 (Poster topic 40)
15:30 Pathology 2 (Poster topic 41)
15:30 Grey matter damage in MS 2 (Poster topic 42)
15:30 Experimental models 2 (Poster topic 43)
15:30 Genetics/transcriptomics 2 (Poster topic 44)
15:30 Immunology 2 (Poster topic 45)
15:30 MS and infections 2 (Poster topic 46)
15:30 Environmental risk factors 2 (Poster topic 47)
15:30 Neurobiology 2 (Poster topic 48)
15:30 Repairing mechanisms 2 (Poster topic 49)
15:30 Imaging 2 (Poster topic 50)
15:30 Neurophysiology 2 (Poster topic 51)
15:30 Neuropsychology and fatigue 2 (Poster topic 52)
15:30 Immunomodulation 2 (Poster topic 53)
15:30 Immunosuppression 2 (Poster topic 54)
15:30 Neuroprotection 2 (Poster topic 55)
15:30 Long-term treatment monitoring 2 (Poster topic 56)
15:30 Risk management for disease-modifying treatments 2 (Poster topic 57)
15:30 Tools for detecting therapeutic response 2 (Poster topic 58)
15:30 Others 2 (Poster topic 59)
15:30 Treatment of specific symptoms 2 (Poster topic 60)
15:30 Comprehensive care & rehabilitation 2 (Poster topic 61)
15:30 Quality of life 2 (Poster topic 62)
15:30 Neuro-Ophthalmology 2 (Poster topic 63)
15:30 Biomarkers 2 (Poster topic 64)
15:30 Chronic cerebro-spinal venous insufficiency (CCSVI) 2 (Poster topic 65)
15:30 Late Breaking News (Poster topic 66)
17:00 CCSVI (Hot Topic 4)
17:00 MS: neurodegeneration (Hot Topic 5)
17:00 Risk management for disease-modifying treatments in MS (Hot Topic 6)
18:00 Almirall
Advances in the management of MS -related spasticity (Satellite Symposium)
19:15 Genzyme, a Sanofi Company
Evolving treatment expectations in MS: where are we going? (Satellite Symposium)
20:30 Conference Dinner at the Beurs van Berlage